Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of an efficient one-step real-time reverse transcription polymerase chain reaction method for severe acute respiratory syndrome-coronavirus-2 detection.
Nakura Y, Wu HN, Okamoto Y, Takeuchi M, Suzuki K, Tamura Y, Oba Y, Nishiumi F, Hatori N, Fujiwara S, Yasukawa K, Ida S, Yanagihara I. Nakura Y, et al. Among authors: hatori n. PLoS One. 2021 Jun 4;16(6):e0252789. doi: 10.1371/journal.pone.0252789. eCollection 2021. PLoS One. 2021. PMID: 34086827 Free PMC article.
Combining machine learning and nanopore construction creates an artificial intelligence nanopore for coronavirus detection.
Taniguchi M, Minami S, Ono C, Hamajima R, Morimura A, Hamaguchi S, Akeda Y, Kanai Y, Kobayashi T, Kamitani W, Terada Y, Suzuki K, Hatori N, Yamagishi Y, Washizu N, Takei H, Sakamoto O, Naono N, Tatematsu K, Washio T, Matsuura Y, Tomono K. Taniguchi M, et al. Among authors: hatori n. Nat Commun. 2021 Jun 17;12(1):3726. doi: 10.1038/s41467-021-24001-2. Nat Commun. 2021. PMID: 34140500 Free PMC article.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
RECAP study group; Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. RECAP study group, et al. Among authors: hatori n. Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38764356
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Muta Y, et al. Among authors: hatori n. Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024. Front Pharmacol. 2024. PMID: 38601470 Free PMC article.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. Kobayashi K, et al. Among authors: hatori n. Diab Vasc Dis Res. 2023 Nov-Dec;20(6):14791641231222837. doi: 10.1177/14791641231222837. Diab Vasc Dis Res. 2023. PMID: 38096503 Free PMC article.
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Tsukamoto S, Kobayashi K, Toyoda M, Hatori N, Kanaoka T, Wakui H, Sakai H, Furuki T, Chin K, Ito S, Suzuki D, Umezono T, Aoyama T, Nakajima S, Hishiki T, Hatori Y, Hayashi M, Shimura H, Minagawa F, Mokubo A, Takihata M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Tsukamoto S, et al. Among authors: hatori n. Hypertens Res. 2024 Mar;47(3):628-638. doi: 10.1038/s41440-023-01464-y. Epub 2023 Oct 17. Hypertens Res. 2024. PMID: 37848562
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kobayashi K, Toyoda M, Hatori N, Tsukamoto S, Kimura M, Sakai H, Furuki T, Chin K, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Degawa H, Hishiki T, Shimura H, Nakajima S, Miyauchi M, Yamamoto H, Hatori Y, Hayashi M, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Kobayashi K, et al. Among authors: hatori n. Cardiovasc Endocrinol Metab. 2023 Sep 28;12(4):e0292. doi: 10.1097/XCE.0000000000000292. eCollection 2023 Dec. Cardiovasc Endocrinol Metab. 2023. PMID: 37779602 Free PMC article.
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine.
Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, Asayama K, Eguchi N, Katsuya T, Tamura K, Sato K, Kanamori A. Kobayashi K, et al. Among authors: hatori n. Hypertens Res. 2023 Nov;46(11):2447-2459. doi: 10.1038/s41440-023-01366-z. Epub 2023 Aug 2. Hypertens Res. 2023. PMID: 37532949
118 results